Abstract: The purpose of this study was to evaluate plasma levels of vasoactive factors which may play a role in the altered vascular tone of pulmonary circulation during hepatic failure. In the 85 patients with hepatic dysfunction studied we obtained: ET-1:0.66+/-0.30, 1.35+/-0.30, 1.73+/-0.41 fmol/ml; Big-ET-1:1.42+/-0.14, 1.91+/-0.22, 2.26+/-0.20 fmol/ml; NO: 58.3+/-2.91, 68.0+/-4.44, 72.12+/-8.73 mumol/l; AM:14.7+/-1.78, 18.9+/-1.70, 23.14+/-3.08 pmol/l; ANP:17.8+/-3.96, 20.7+/-4.66, 23.7+/-5.25 pg/ml; BNP:27.4+/-6.23, 49.0+/-17.7, 63.5+/-16.1 pg/ml; DNP:230.8+/-18.6, 287.3+/-19.6, 270.7+/-27.8 pg/ml for Child-Pugh class A n=20, class B n=36, class C n=29, respectively. The vasoactive peptide increase, associated with the progression of hepatic dysfunction, suggests that they may, by the way, contribute to circulatory and gas exchange modifications.

Hepatopulmonary syndrome and vasoactive factors

2003

Abstract

Abstract: The purpose of this study was to evaluate plasma levels of vasoactive factors which may play a role in the altered vascular tone of pulmonary circulation during hepatic failure. In the 85 patients with hepatic dysfunction studied we obtained: ET-1:0.66+/-0.30, 1.35+/-0.30, 1.73+/-0.41 fmol/ml; Big-ET-1:1.42+/-0.14, 1.91+/-0.22, 2.26+/-0.20 fmol/ml; NO: 58.3+/-2.91, 68.0+/-4.44, 72.12+/-8.73 mumol/l; AM:14.7+/-1.78, 18.9+/-1.70, 23.14+/-3.08 pmol/l; ANP:17.8+/-3.96, 20.7+/-4.66, 23.7+/-5.25 pg/ml; BNP:27.4+/-6.23, 49.0+/-17.7, 63.5+/-16.1 pg/ml; DNP:230.8+/-18.6, 287.3+/-19.6, 270.7+/-27.8 pg/ml for Child-Pugh class A n=20, class B n=36, class C n=29, respectively. The vasoactive peptide increase, associated with the progression of hepatic dysfunction, suggests that they may, by the way, contribute to circulatory and gas exchange modifications.
2003
Istituto di Fisiologia Clinica - IFC
Inglese
Source: EUROMEDLAB 2003: PROCEEDINGS OF THE 15TH IFCC-FESCC EUROPEAN CONGRESS OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE Pages: 315-318 Published: 2003
315
318
88-323-3128-4
MONDUZZI EDITORE
BOLOGNA
ITALIA
Conference: 15th IFCC/FESCC European Congress of Clinical Chemistry and Laboratory Medicine Location: BARCELONA, SPAIN Date: JUN 01-05, 2003 Sponsor(s): IFCC; FESCC
7
02 Contributo in Volume::02.01 Contributo in volume (Capitolo o Saggio)
268
none
S Del Ry S, Del Ry; G Catapano G, Catapano; M Maltinti M, Maltinti; F Mannucci F, Mannucci; C Bauleo C, Bauleo; R Prediletto R, Prediletto; D Gianness...espandi
info:eu-repo/semantics/bookPart
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/177945
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact